S&P 500   4,356.59 (+0.61%)
DOW   34,151.54 (+0.24%)
QQQ   361.26 (+0.95%)
AAPL   176.40 (+1.42%)
MSFT   320.39 (+0.27%)
META   303.33 (+2.57%)
GOOGL   131.67 (+0.94%)
AMZN   131.70 (+1.83%)
TSLA   254.95 (-0.29%)
NVDA   419.81 (+2.35%)
NIO   8.58 (+1.54%)
BABA   88.07 (+4.71%)
AMD   98.04 (+2.01%)
T   15.08 (-1.50%)
F   12.56 (+2.95%)
MU   69.19 (+1.90%)
CGC   0.83 (+8.56%)
GE   112.98 (+-0.01%)
DIS   82.28 (-0.54%)
AMC   7.99 (+3.77%)
PFE   32.79 (-0.18%)
PYPL   58.75 (+0.22%)
NFLX   383.94 (-0.05%)
S&P 500   4,356.59 (+0.61%)
DOW   34,151.54 (+0.24%)
QQQ   361.26 (+0.95%)
AAPL   176.40 (+1.42%)
MSFT   320.39 (+0.27%)
META   303.33 (+2.57%)
GOOGL   131.67 (+0.94%)
AMZN   131.70 (+1.83%)
TSLA   254.95 (-0.29%)
NVDA   419.81 (+2.35%)
NIO   8.58 (+1.54%)
BABA   88.07 (+4.71%)
AMD   98.04 (+2.01%)
T   15.08 (-1.50%)
F   12.56 (+2.95%)
MU   69.19 (+1.90%)
CGC   0.83 (+8.56%)
GE   112.98 (+-0.01%)
DIS   82.28 (-0.54%)
AMC   7.99 (+3.77%)
PFE   32.79 (-0.18%)
PYPL   58.75 (+0.22%)
NFLX   383.94 (-0.05%)
S&P 500   4,356.59 (+0.61%)
DOW   34,151.54 (+0.24%)
QQQ   361.26 (+0.95%)
AAPL   176.40 (+1.42%)
MSFT   320.39 (+0.27%)
META   303.33 (+2.57%)
GOOGL   131.67 (+0.94%)
AMZN   131.70 (+1.83%)
TSLA   254.95 (-0.29%)
NVDA   419.81 (+2.35%)
NIO   8.58 (+1.54%)
BABA   88.07 (+4.71%)
AMD   98.04 (+2.01%)
T   15.08 (-1.50%)
F   12.56 (+2.95%)
MU   69.19 (+1.90%)
CGC   0.83 (+8.56%)
GE   112.98 (+-0.01%)
DIS   82.28 (-0.54%)
AMC   7.99 (+3.77%)
PFE   32.79 (-0.18%)
PYPL   58.75 (+0.22%)
NFLX   383.94 (-0.05%)
S&P 500   4,356.59 (+0.61%)
DOW   34,151.54 (+0.24%)
QQQ   361.26 (+0.95%)
AAPL   176.40 (+1.42%)
MSFT   320.39 (+0.27%)
META   303.33 (+2.57%)
GOOGL   131.67 (+0.94%)
AMZN   131.70 (+1.83%)
TSLA   254.95 (-0.29%)
NVDA   419.81 (+2.35%)
NIO   8.58 (+1.54%)
BABA   88.07 (+4.71%)
AMD   98.04 (+2.01%)
T   15.08 (-1.50%)
F   12.56 (+2.95%)
MU   69.19 (+1.90%)
CGC   0.83 (+8.56%)
GE   112.98 (+-0.01%)
DIS   82.28 (-0.54%)
AMC   7.99 (+3.77%)
PFE   32.79 (-0.18%)
PYPL   58.75 (+0.22%)
NFLX   383.94 (-0.05%)
NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News

$155.52
-3.99 (-2.50%)
(As of 11:27 AM ET)
Compare
Today's Range
$154.00
$161.72
50-Day Range
$159.51
$225.77
52-Week Range
$57.21
$322.67
Volume
113,134 shs
Average Volume
365,194 shs
Market Capitalization
$2.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$309.18

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
93.8% Upside
$309.18 Price Target
Short Interest
Bearish
15.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.46mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($18.77) to ($8.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

146th out of 965 stocks

Pharmaceutical Preparations Industry

50th out of 452 stocks


MDGL stock logo

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Price History

MDGL Stock News Headlines

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
The Latest Analyst Ratings for Madrigal Pharmaceuticals
John Paulson's Q2 2023 13F Filing Update
See More Headlines
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Company Calendar

Last Earnings
8/08/2023
Today
9/22/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
92
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$309.18
High Stock Price Forecast
$390.00
Low Stock Price Forecast
$224.00
Forecasted Upside/Downside
+93.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-295,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.54 per share

Miscellaneous

Free Float
14,053,000
Market Cap
$2.95 billion
Optionable
Optionable
Beta
-0.72

Social Links

10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Rebecca A. Taub M.D. (Age 71)
    Founder, Chief Medical Officer, Pres of R&D and Director
    Comp: $939.83k
  • Mr. Alex G. Howarth (Age 54)
    Sr. VP & CFO
    Comp: $757.26k
  • Mr. Brian J. Lynch J.D. (Age 61)
    Sr. VP & Gen. Counsel
    Comp: $763.75k
  • Mr. Remy Sukhija (Age 51)
    Sr. VP & Chief Commercial Officer
    Comp: $785.2k
  • Mr. William J. Sibold (Age 57)
    CEO & Director
  • Dr. Kianoush Motesharei Ph.d. (Age 53)
    Sr. VP of Bus. & Corp. Devel.
  • Mr. Edward Chiang
    Sr. VP of Clinical & Technical Operations
  • Mr. Thomas W. Hare
    Sr. VP of Clinical Management
  • Dr. Robert E. Waltermire Ph.D. (Age 59)
    Chief Pharmaceutical Devel. Officer
  • Dr. Stephen Dodge M.B.A.
    Pharm.D., Sr. VP of Global Medical Affairs













MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price forecast for 2023?

11 brokerages have issued twelve-month price objectives for Madrigal Pharmaceuticals' stock. Their MDGL share price forecasts range from $224.00 to $390.00. On average, they predict the company's stock price to reach $309.18 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2023?

Madrigal Pharmaceuticals' stock was trading at $290.25 at the start of the year. Since then, MDGL stock has decreased by 45.0% and is now trading at $159.51.
View the best growth stocks for 2023 here
.

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MDGL earnings forecast
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($4.69) earnings per share for the quarter, missing the consensus estimate of ($4.59) by $0.10.

What ETFs hold Madrigal Pharmaceuticals' stock?
What other stocks do shareholders of Madrigal Pharmaceuticals own?
What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.65%), State Street Corp (2.94%), Assenagon Asset Management S.A. (2.55%), Marshall Wace LLP (2.49%), Alliancebernstein L.P. (2.01%) and Perceptive Advisors LLC (1.64%). Insiders that own company stock include Brian Joseph Lynch, Remy Sukhija and Richard S Levy.
View institutional ownership trends
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $159.51.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $2.95 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.65) on an earnings per share basis.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -